Free Trial
NASDAQ:ASRT

Assertio (ASRT) Stock Price, News & Analysis

$1.00
0.00 (0.00%)
(As of 05/28/2024 ET)
Today's Range
$1.00
$1.03
50-Day Range
$0.75
$1.22
52-Week Range
$0.73
$6.57
Volume
816,277 shs
Average Volume
768,155 shs
Market Capitalization
$95.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.58

Assertio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
358.3% Upside
$4.58 Price Target
Short Interest
Bearish
11.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.07mentions of Assertio in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$11,481 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.13) to $0.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.64 out of 5 stars

Medical Sector

640th out of 931 stocks

Pharmaceutical Preparations Industry

289th out of 427 stocks

ASRT stock logo

About Assertio Stock (NASDAQ:ASRT)

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

ASRT Stock Price History

ASRT Stock News Headlines

Sig Kirk Joins Assertio Board of Directors
Q4 2023 Assertio Holdings Inc Earnings Call
Recap: Assertio Holdings Q4 Earnings
See More Headlines
Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2024
Today
5/29/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ASRT
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.58
High Stock Price Target
$7.00
Low Stock Price Target
$2.75
Potential Upside/Downside
+450.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-331,940,000.00
Net Margins
-234.40%
Pretax Margin
-177.99%

Debt

Sales & Book Value

Annual Sales
$152.07 million
Cash Flow
$0.73 per share
Book Value
$1.46 per share

Miscellaneous

Free Float
92,081,000
Market Cap
$95.12 million
Optionable
Optionable
Beta
1.00
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

ASRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Assertio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASRT shares.
View ASRT analyst ratings
or view top-rated stocks.

What is Assertio's stock price target for 2024?

2 equities research analysts have issued twelve-month target prices for Assertio's shares. Their ASRT share price targets range from $2.75 to $7.00. On average, they expect the company's share price to reach $4.58 in the next year. This suggests a possible upside of 358.3% from the stock's current price.
View analysts price targets for ASRT
or view top-rated stocks among Wall Street analysts.

How have ASRT shares performed in 2024?

Assertio's stock was trading at $1.07 at the beginning of the year. Since then, ASRT stock has decreased by 6.5% and is now trading at $1.00.
View the best growth stocks for 2024 here
.

Are investors shorting Assertio?

Assertio saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 10,730,000 shares, a decline of 6.6% from the April 30th total of 11,490,000 shares. Based on an average trading volume of 989,400 shares, the short-interest ratio is presently 10.8 days.
View Assertio's Short Interest
.

When is Assertio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our ASRT earnings forecast
.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) issued its quarterly earnings data on Monday, May, 6th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.04. The business had revenue of $32.45 million for the quarter, compared to analyst estimates of $28.93 million. Assertio had a positive trailing twelve-month return on equity of 10.80% and a negative net margin of 234.40%.

What guidance has Assertio issued on next quarter's earnings?

Assertio issued an update on its FY 2024 earnings guidance on Monday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $110.0 million-$125.0 million, compared to the consensus revenue estimate of $117.4 million.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK).

Who are Assertio's major shareholders?

Assertio's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.17%), Russell Investments Group Ltd. (2.47%), Empowered Funds LLC (0.40%), TSP Capital Management Group LLC (0.23%), Denali Advisors LLC (0.17%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Heather L Mason, James L Tyree, Paul Schwichtenberg, Sam Schlessinger and William Mckee.
View institutional ownership trends
.

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASRT) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners